11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT
    2.
    发明申请
    11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT 审中-公开
    11-(2-吡咯烷-1-基 - 乙氧基)-14,19-二氧杂环己烯-5,7,26-三唑并[3,4-b] [19.3.1.1(2,6).1(8,12)] HEPTACOSA-1( 25),2(26),3,5,8,10,12(27),16,21,23 - 十六烷基硫酸盐

    公开(公告)号:US20150322084A1

    公开(公告)日:2015-11-12

    申请号:US14621726

    申请日:2015-02-13

    Abstract: The present invention relates to certain salts of a 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (Compound I) which have been found to have improved properties. In particular the present invention relates to the citrate salt of this compound. The invention also relates to pharmaceutical compositions containing the citrate salt and methods of use of the citrate salt in the treatment of certain medical conditions.

    Abstract translation: 本发明涉及11-(2-吡咯烷-1-基 - 乙氧基)-14,19-二氧杂-5,7,26-三氮杂 - 四环[19.3.1.1(2,6).1( 8,12)],已被发现具有改善的性能的十七酸-1(25),2(26),3,5,8,10,12(27),16,21,23-十氢烯(化合物I)。 特别地,本发明涉及该化合物的柠檬酸盐。 本发明还涉及含有柠檬酸盐的药物组合物和柠檬酸盐在使用某些医疗条件下的使用方法。

Patent Agency Ranking